TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV, L3
Teva Pharmaceutical Industries Issues €1B and $1B in Senior Notes
Other Events
Announces Successful Pricing of $4.9 Billion (Equivalent) Senior Notes
Recasts Historical Segment Information in Annual Report
Material Modification to Rights of Security Holders - Teva Pharmaceutical
Financial Results, Press Release
Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution, To Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Pivot to Growth Strategy
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
Amended Registration of Securities
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Definitive Proxy Statement
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Notification Filed by a National Security Exchange
Free Writing Prospectus
Post-Effective Amendment to a Registration Statement for Depositary Shares
Specialized Disclosure Report